Interojo Co

Interojo Co EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of Interojo Co (119610.KQ) as of Nov 20, 2026 is 9.68. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was 32.04 — a change of -69.80% (lower).

EV/EBITDA

9.68

YoY

-69.80%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of Interojo Co is 2025 9.68 . EV/EBITDA (Enterprise Value to EBITDA) of Interojo Co was 2024 32.04 . It decreases by -69.80% lower compared to the previous year.

The Interojo Co EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2018
10.29 KRW
Jan 1, 2019
7.47 KRW
Jan 1, 2020
11.91 KRW
Jan 1, 2021
6.34 KRW
Jan 1, 2022
6.49 KRW
Jan 1, 2023
39.19 KRW
Jan 1, 2024
32.04 KRW
Jan 1, 2025
9.68 KRW
The Interojo Co EV/EBITDA history
YEAREV/EBITDAYoY
9.68-69.80%
32.04-18.24%
39.19+504.29%
6.49+2.21%
6.34-46.71%
11.91+59.35%
7.47-27.37%
10.29+42.24%
7.23-2.73%
7.44-32.85%
11.07-47.35%
21.03—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Interojo Co Stock analysis

What does Interojo Co do? Interojo Co Ltd manufactures and sells contact lenses including silicone hydrogel lenses, sodium hyaluronate lenses, frequent replacement lenses, conventional lenses, toric lenses, multifocal vision lenses, color lenses, therapy and bandage lenses, and rigid gas permeable (RGP) contact lenses along with solutions. The company distributes its products in domestic and overseas markets, targeting both retail consumers and healthcare providers who purchase lenses for patient use. Its product range caters to diverse vision correction needs, from standard to specialized medical applications, with solutions supporting lens care and usage. The firm's primary revenue streams come from the sale of contact lenses and associated solutions to customers in both domestic and international markets. Products like silicone hydrogel lenses and RGP contact lenses represent key offerings for everyday wear and specialized vision correction, while therapy and bandage lenses serve medical applications requiring professional oversight. The company's domestic market presence complements its overseas distribution, ensuring broad accessibility across different customer segments. Interojo Co Ltd's business model focuses on direct sales of its comprehensive product portfolio to end-users and healthcare institutions. The company's product lines address various vision correction scenarios, from routine daily use with frequent replacement lenses to advanced medical needs with therapy lenses. By maintaining a diverse range of contact lenses and solutions, the company serves both consumer and professional markets without relying on third-party partnerships or additional services. Interojo Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Interojo Co stock

EV/EBITDA (Enterprise Value to EBITDA) of Interojo Co is 9.68 in 2025.

EV/EBITDA (Enterprise Value to EBITDA) of Interojo Co changed from 32.04 to 9.68, representing a -69.80% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Interojo Co since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Interojo Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Interojo Co

All Key Metrics — Interojo Co